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Abstract
Background: Myostatin (MSTN), a member of the TGF-β superfamily, has been identified as a
negative regulator of skeletal muscle mass. Inactivating mutations in the MSTN gene are responsible
for the development of a hypermuscular phenotype. In this study, we performed transcriptomic
and proteomic analyses to detect altered expression/abundance of genes and proteins. These
differentially expressed genes and proteins may represent new molecular targets of MSTN and
could be involved in the regulation of skeletal muscle mass.
Results: Transcriptomic analysis of the Quadriceps muscles of 5-week-old MSTN-null mice (n = 4)
and their controls (n = 4) was carried out using microarray (human and murine oligonucleotide
sequences) of 6,473 genes expressed in muscle. Proteomic profiles were analysed using two-
dimensional gel electrophoresis coupled with mass spectrometry. Comparison of the
transcriptomic profiles revealed 192 up- and 245 down- regulated genes. Genes involved in the
PI3K pathway, insulin/IGF pathway, carbohydrate metabolism and apoptosis regulation were up-
regulated. Genes belonging to canonical Wnt, calcium signalling pathways and cytokine-receptor
cytokine interaction were down-regulated. Comparison of the protein profiles revealed 20 up- and
18 down-regulated proteins spots. Knockout of the MSTN gene was associated with up-regulation
of proteins involved in glycolytic shift of the muscles and down-regulation of proteins involved in
oxidative energy metabolism. In addition, an increased abundance of survival/anti-apoptotic factors
were observed.
Conclusion: All together, these results showed a differential expression of genes and proteins
related to the muscle energy metabolism and cell survival/anti-apoptotic pathway (e.g. DJ-1, PINK1,
14-3-3ε protein, TCTP/GSK-3β). They revealed the PI3K and apoptotic pathways as MSTN targets
and are in favour of a role of MSTN as a modulator of cell survival in vivo.
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Background
Myostatin (MSTN), a member of the TGF-β superfamily,
has emerged as a key factor of muscle development and
maintenance of muscle mass homeostasis [1]. This has
strengthened the idea that MSTN is a potential target for
novel therapeutic strategies to improve the disease symp-
toms with potential long-term benefits in a variety of mus-
cular dystrophies [2], or for improving the management
of muscular growth in livestock animals [3].
Inactivating mutations of the MSTN gene are responsible
for the development of a hypermuscular phenotype in cat-
tle [4,5], dogs [6], mice [7] and humans [8]. The hyper-
muscular phenotype associated with constitutive MSTN
loss-of-function results from both hyperplasia (increased
number of fibers) and hypertrophy (increased size of indi-
vidual fibers). An hypermuscular phenotype of the same
magnitude as that observed for constitutive knockout has
also been observed in mice with a conditional MSTN
knockout (postnatal inactivation of MSTN) generated by
a Cre-Lox system [9]. This demonstrated that MSTN mod-
ulates the muscle mass throughout development. The
ability of MSTN to control myoblast cell proliferation and
differentiation has been demonstrated. Examination of
the molecular action of MSTN has revealed an inhibitory
influence on proliferation through the control of cell cycle
progression [10,11]. MSTN also inhibits myoblast differ-
entiation [12] partially through a decreased expression of
Myogenic Regulatory Factors (reviewed by [13]). Myo-
genin and p21CKI have been identified as the major phys-
iological targets of endogenous MSTN in murine cells
[14]. MSTN has also been shown to negatively regulate
satellite cell activation and self-renewal [15] and this
action may involve a regulation of Pax7 [16]. Further-
more, we recently demonstrated that MSTN can regulate
satellite cell proliferation via regulation of WNT4 [17].
Recent data established that MSTN induces muscle atro-
phy. In mice, muscle disuse-induced atrophy generated by
hindlimb unloading is associated with a reversible
increase in MSTN mRNA abundance [18]. MSTN has been
implicated in muscle wasting in various diseases (HIV,
cachexia, cancer, Duchenne's muscular dystrophy) and
ageing [19]. Transgenic mice that overexpress MSTN selec-
tively in skeletal muscle have lower muscle mass [20]. In
adult rats, ectopic MSTN expression induces atrophy of
skeletal muscle as shown by a significant decrease in mus-
cle mass, fiber cross-sectional area and protein content
[21]. This is associated with decreased expression of genes
structural proteins (myosin heavy chain IIb, troponin I
and desmin) and myogenic transcription factors. Moreo-
ver, inhibition of MSTN rescues the muscular atrophy of
caveolin-3-deficient mice [22] and protects against muscle
atrophy due to glucocorticoid treatment [23]. If some of
the mechanisms by which MSTN contributes to atrophy
have been clarified, e.g. FOXO1 activation and subse-
quent activation of ubiquitin proteolytic system [24], the
relative contribution of MSTN to the regulation of the bal-
ance between atrophic and hypertrophic processes in
muscle remains to be further elucidated. Some questions
remain to be answered such as the possibility that MSTN
might inhibit muscle hypertrophy rather than induce
atrophy [24,25].
We have previously analysed the metabolic profile of dou-
ble-muscled cattle [26] and more recently the molecular
profiles in muscle in the context of MSTN loss-of-function
[27,28] and hypothesised that these should help in the
understanding of molecular mechanisms by which MSTN
regulates muscle mass homeostasis. The main objective of
the present study was to identify MSTN targets involved in
the regulation of muscle mass. For this, we examined the
transcriptional and proteomic profiles in the Quadriceps
muscle of MSTN-null mice and their control littermates.
The originality of this work was to combine two genomic
approaches, namely transcriptomics and proteomics, pro-
viding complementary data.
Results
Transcriptomic profiles in myostatin-null mice muscle
To search for novel candidate MSTN targets, we used oli-
gonucleotide microarrays (human and murine oligonu-
cleotide sequences) of 6,473 genes expressed in muscle.
We examined mRNA expression in individual samples
from 4 constitutive MSTN-null and 4 control littermates.
A reference sample allowing hybridization with detection
of 57 to 68% reliable spots was used to compare the pat-
terns of muscle gene expression between groups of mice.
The hybridization results showed that, among 6,473
genes represented on the chip, an average of 2,496 (39%)
gave valid expression values. Significance analysis of
microarray (SAM) was conducted to detect statistically sig-
nificant expression changes. In total, SAM analysis
revealed the differential expression of 192 up- and 245
down- regulated genes (FDR <5%, see additional files 1
and 2).
Bioinformatic analysis indicated that genes belonging to
the Phosphatidyl Inositol 3-kinase (PI3K) pathway, insu-
lin/IGF pathway protein kinase β signalling, carbohydrate
metabolism, cell differentiation were up-regulated (Table
1). Conversely, genes belonging to the canonical Wnt sig-
nalling pathway, calcium signalling pathway and
cytokine-cytokine receptor interaction were down-regu-
lated (Table 1). Twenty-three of the differentially
expressed genes encoded for transcription factors of which
8 were up-regulated (e.g. foxa3) and 15 were down-regu-
lated (e.g. Lef1).
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Expression of upstream components of the PI3K survival
pathway (Akt, GSK-3β) were surveyed. The steady-state
level of Akt mRNA (Table 1) and phosphorylated protein
(Table 2) were increased in the muscles of MSTN-null
mice. Differential expression of the GSK-3β was con-
firmed by qPCR and western-blot (Table 2) analyses. In
addition, the ratio of serine-9 phosphorylated GSK-3β/
GSK-3β ration was increased, which illustrates GSK-3β
activation in MSTN-null versus wild-type skeletal muscle
(Table 2).
Proteomic profiles in myostatin-null mice muscle
We have used two-dimensional polyacrylamide gel elec-
trophoresis, high-throughput image analysis and candi-
date picking, coupled with mass spectrophotometry to
investigate the proteome profile of MSTN-null mice vs
control littermates. Comparison of the protein profiles
using SAM (FDR <5%) revealed the differential abun-
dance of 38 protein spots (20 up-regulated and 18 down-
regulated) in MSTN-null mice vs wild-type controls. Mass
spectrometry analyses allowed the identification of the
candidate spots (Table 3). Differential expression was
confirmed for some selected proteins by western-blot
analysis (Table 2).
Bioinformatic analysis indicated that most of the differen-
tial proteins were related to muscle energy metabolism.
Enzymes of the citrate cycle (e.g. pyruvate dehydrogenase
lipoamide, dihydrolipoamide S-acetyl transferase E2, iso-
citate dehydrogenase, Succinate dehydrogenase) and the
respiratory chain (e.g. ATP synthase F1 beta, ATP synthase
D chain, ubiquinol cytochrome c reductase core protein 1,
Table 1: Distribution of differential genes in myostatin-null mice vs control mice according to KEGG pathways.
#Entity KEGG Down regulated genes N = Up regulated genes N = Unadj. P value Adj. P value
Phosphatidylinositol 
signaling system
No genes 0 Inppl1, PIK3R3, PIK3CG 
PLCG1
Insulin signaling pathway Gsk3b 1 Ppp1cb, PTPRF, PIK3R3, 
PIK3CG, PRKAR1B
5 1.05E-01 1
mTOR signaling pathway No genes 0 MO25, PIK3R3, PIK3CG 3 1.09E-01 1
Chronic myeloid 
leukemia
No genes 0 PIK3R3, PIK3CG, Abl1 3 1.09E-01 1
T cell receptor signaling 
pathway
No genes 0 PIK3R3, PIK3CG, PLCG1 3 1.09E-01 1
Fructose and mannose 
metabolism
Akr1e1, PMM2, Khk, OGT 4 No genes 0 1.19E-01 1
ECM-receptor 
interaction
LAMC3, Col4a2, COL6A1, 
ITGB8, ITGA9
5 Col4a4 1 2.08E-01 1
Calcium signaling 
pathway
PDE1B, Camk2a, CAMK4, 
Cacna1i, HTR2A, ADORA2A
6 PLCG1, Ptgfr 2 2.74E-01 1
Regulation of actin 
cytoskeleton
Limk1, ARPC4 ITGB8, ITGA9 4 FGF6, Ppp1cb, PIK3R3, 
PIK3CG, CFL2, Actb, MYL1
7 3.50E-01 1
MAPK signaling pathway Cacna1i 1 MAP2K7, FGF6, PLA2G6 3 3.51E-01 1
Natural killer cell 
mediated cytotoxicity
KLRC2 1 PIK3R3, PIK3CG, PLCG1 3 3.51E-01 1
Apoptosis Atm 1 PIK3R3, PIK3CG, PRKAR1B 3 3.51E-01 1
Wnt signaling pathway Gsk3b, LRP5, Camk2a, LEF1 4 CCND3 1 3.65E-01 1
Leukocyte 
transendothelial 
migration
Cxcl15, Cxcl13 2 PIK3R3, PIK3CG, Actb, PLCG1 4 4.27E-01 1
Cytokine-cytokine 
receptor interaction
IL23A Cxcl15, CXCR3, IL17, 
Cxcl13
5 CCL22, CCR7 2 4.40E-01 1
Toll-like receptor 
signaling pathway
Irf3 1 PIK3R3, PIK3CG 2 6.09E-01 1
B cell receptor signaling 
pathway
Gsk3b 1 PIK3R3, PIK3CG 2 6.09E-01 1
GnRH signaling pathway Camk2a 1 MAP2K7, PLA2G6 2 6.09E-01 1
Axon guidance Limk1, Gsk3b, Epha2 3 SEMA3A, Abl1, CFL2, EFNA4 4 7.10E-01 1
Focal adhesion LAMC3, Gsk3b, Col4a2, 
COL6A1, ITGB8, ITGA9
6 CCND3, Ppp1cb, PIK3R3, 
PIK3CG, Actb, Col4a4
6 1 1
Hedgehog signaling 
pathway
Gsk3b 1 Gas1 1 1 1
Alzheimer's disease Gsk3b, Apoe 2 LRP1 1 1 1
N: Number of genes involved in each biological process; Unadj. P value: Unadjusted P value, P value from Fisher's exact test without adjusting for 
multiple comparisons; Adj. P value: adjusted P value, after correction for multiple testing.
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NADH-ubiquinone oxidoreductase), and the heart-fatty
acid binding protein (H-FABP) were down-regulated
(Table 2; Table 3). Conversely two fragments of Glycogen
phosphorylase, and enolase 1 (an enzyme of the glycoly-
sis/gluconeogenesis pathway) were up-regulated (Table
3). Abundance levels of Guanidinoacetate methyltrans-
ferase, which catalyzes the last step of creatine biosynthe-
sis, purine nucleoside phosphorylase, which catalyzes the
reversible cleavage of inosine and guanosine to their
respective bases hypoxanthine and guanine, and the ade-
nylate kinase 1, which is an important enzyme in cellular
adenine nucleotide homeostasis, were also increased.
Myosin-binding protein H, which is a protein involved in
the contractile apparatus, was revealed to be up-regulated
in MSTN-null mice vs wild-type controls and this was con-
firmed by western-blot analysis (Table 2). Fast glycolytic
Myosin Heavy chain isoforms (MyHCII) were also more
abundant in MSTN-null mice vs wild-type controls in
western-blot experiments (Table 2). α1-Syntrophin was
found to be up-regulated in MSTN-null mice (Table 2;
Table 3). All together, these data are representative of
greater fast glycolytic metabolism in the muscle of MSTN-
null mice.
A differential abundance of survival/mortality factors and
some chaperones (Table 3) was also detected with the
down regulation of Hsp alpha crystallin-related B6, Hsp
9A (mortalin), and the up-regulation of Tcp1, TCTP, DJ-1,
and 14-3-3E. The differential abundance levels were con-
firmed by western-blot analyses for mortalin, DJ-1, TCTP
and 14-3-3E (Table 2 and Figure 1). All together these data
indicate that myostatin inactivation was associated with
up-regulation of survival/anti-apoptotic factors, in favour
to increased cell survival.
Discussion
In this study, we have looked for novel myostatin targets
and mechanisms involved in the control of muscle home-
ostasis. For this, we have used a functional genomics strat-
egy, which combined both transcriptomic and proteomic
profiling of MSTN-null vs wild-type control skeletal mus-
cle. We hypothesized that examination of molecular pro-
files in the muscles of young growing mice in the context
of MSTN loss-of-function would allow the identification
of myostatin downstream targets. However any changes in
gene and protein expression may also reflect conse-
quences of loss of MSTN function. Anyway, this approach
should give information on direct or indirect MSTN tar-
gets by revealing altered physiological pathways. A similar
percentage of genes (17.5%) and proteins (15.3%) were
declared to be differentially expressed with both tech-
niques as indicated by the ratio of the number of differen-
tial genes and proteins to the total number of genes
spotted on chips and proteins detected in 2-DE gels in the
Table 2: Differential expression of myostatin targets genes confirmed by qPCR and by western-blot experiments in MSTN-null mice vs 
their control littermates.
Proteomics Transcriptomics qPCR Western-Blot
H-FABP -2.1 -9.1
MYBPH 3.1 1.4
MyHCII 4.9
Syntrophin A 1.5 2.8
p-Akt 2.2
GSK-3β -1.9 -2.4
GSK-3β(ser9)/GSK-3β 1.7 t
PI3KR3 1.1 1.8
DJ-1 1.5 1.7 2.2
PINK1 1.9 3.4
PTEN -1.6 t -1.6
Mortalin -1.5 -1.4 -2.1
TCTP 2.7 1.6
14-3-3E 1.8 1.4 1.7
mfgf6 1.9
Results are expressed as Fold Changes and all the differences have been declared significant (P < 0.05) except for some tendencies (t: P < 0.10).
H-FABP: Heart-Fatty acid binding protein H; MyBP-H: Myosin binding protein H; MyHCII: fast myosin heavy chain isoform; pAkt: phosphorylated 
Akt; GSK-3β: Glycogen synthase kinase 3β; GSK-3β (ser9): Glycogen synthase kinase 3β (phosphorylated at serine 9); PI3KR3: Phosphatidylinositol 
3-kinase regulatory subunit; DJ-1: cancer- and Parkinson's disease-associated protein (park7); PINK1: PTEN-induced putative kinase 1; PTEN: 
tumour-suppressor phosphatase with tensin homology. TCTP: Translationally controlled tumor protein; 14-3-3E: 14-3-3ε protein; mfgf6: murine 
Fibroblast growth factor 6.
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Table 3: Differentially expressed muscle proteins in myostatin-null mice vs control mice.
Spot no. Protein name Relevant Swiss Prot Accession number pI Mr (kDa) FC
1781 Eef1g protein [Mus musculus] Q8R1N8_MOUSE 7.02 37.178 Increased 2.8
1735 Adenylate kinase 1 [Mus musculus] KAD1_MOUSE 5.67 21.64 Increased 1.5
1728 DJ-1 protein [Mus musculus] PARK7_MOUSE 6.32 20.236 Increased 1.5
1690 NADH dehydrogenase (ubiquinone) Fe-S 
protein 3 [Mus musculus]
NDUS3_MOUSE 6.67 30.302 Increased 1.7
1690 Guanidinoacetate methyltransferase [Mus 
musculus]
GAMT_MOUSE 5.43 26.604 Increased 1.7
1663 Capping protein (actin filament) muscle 
Z-line, beta isoform a [Mus musculus]
A2AMV4_MOUSE 5.47 31.611 Increased 1.4
1593 Capping protein (actin filament) muscle 
Z-line, alpha 2 [Mus musculus]
Q3UBZ3_MOUSE 5.57 33.118 Increased 1.4
1673 Muscle glycogen phosphorylase [Mus 
musculus]
PYGM_MOUSE 6.65 97.681 Increased 2.4
1894 Glycogen phosphorylase, muscle form (EC 
2.4.1.1) (Myophosphorylase) [Mus musculus]
PYGM_MOUSE 6.65 97.094 Increased 1.7
1393 Enolase 1, alpha non-neuron [Mus musculus] ENOA_MOUSE 6.37 47.453 Increased 1.3
1230 t-complex protein 1 [Mus musculus] TCPA1_MOUSE 5.82 60.867 Increased 1.7
1164 Myosin binding protein H [Mus musculus] MYBPH_MOUSE 6.21 53.065 Increased 3.1
1166 Myosin binding protein H [Mus musculus] MYBPH_MOUSE 6.09 53.065 Increased 1.5
1731 Translationally-controlled tumor protein 
(TCTP) (p23) (21 kDa polypeptide) (p21) 
[Mus musculus]
TCTP_MOUSE 4.76 19.45 Increased 2.7
1703 14-3-3 protein epsilon (14-3-3E) [Mus 
musculus]
1433E_MOUSE 4.63 29.155 Increased 1.8
1706 Calpain small subunit 1 (CSS1) (Calcium-
dependent protease small subunit 1) [Mus 
musculus]
CPNS1_MOUSE 5.41 28.445 Increased 1.4
1718 Proteasome subunit beta type 4 precursor 
(EC 3.4.25.1) (Proteasome beta chain) [Mus 
musculus]
PSB4_MOUSE 5.47 29.097 Increased 1.4
1980 Purine nucleoside phosphorylase (EC 
2.4.2.1) (Inosine phosphorylase) (PNP) [Mus 
musculus]
PNPH_MOUSE 5.78 32.256 Increased 2.9
1427 Alpha-1-syntrophin [Mus musculus] SNTA1_MOUSE 6.4 53.632 Increased 1.5
1804 Fatty acid binding protein 3, muscle and 
heart [Mus musculus]
FABPH_MOUSE 5.75 14.81 Decreased 2.1
1803 Fatty acid binding protein 3, muscle and 
heart [Mus musculus]
FABPH_MOUSE 6.11 14.81 Decreased 2.1
1764 heat shock protein, alpha-crystallin-related, 
B6 [Mus musculus]
HSPB6_MOUSE 5.64 17.567 Decreased 1.8
1620 Pyruvate dehydrogenase (lipoamide) beta 
[Mus musculus]
ODPB_MOUSE 6.41 39.254 Decreased 1.4
1571 Lactate dehydrogenase 2, B chain [Mus 
musculus]
LDHB_MOUSE 5.7 36.834 Decreased 2.4
1541 Isocitrate dehydrogenase 3 (NAD+) alpha 
[Mus musculus]
IDH3A_MOUSE 6.27 40.069 Decreased 1.3
1534 Isocitrate dehydrogenase 3 (NAD+) alpha 
[Mus musculus]
IDH3A_MOUSE 6.27 40.069 Decreased 1.6
1407 Ubiquinol-cytochrome c reductase core 
protein 1 [Mus musculus]
QCR1_MOUSE 5.81 53.446 Decreased 1.3
1373 ATP synthase, H+ transporting 
mitochondrial F1 complex, beta subunit 
[Mus musculus]
AT5F1_MOUSE 5.19 56.265 Decreased 2.3
1178 Dihydrolipoamide S-acetyltransferase (E2 
component of pyruvate dehydrogenase 
complex) [Mus musculus]
ODP2_MOUSE 8.81 68.473 Decreased 1.5
1084 Heat shock protein 9A [Mus musculus] GRP75_MOUSE 5.91 73.768 Decreased 1.5
1691 NADH-ubiquinone oxidoreductase 30 kDa 
subunit, mitochondrial precursor [Mus 
musculus]
NUGM_MOUSE 6.4 30.189 Decreased 1.3
1139 Serum albumin precursor [Mus musculus] ALBU_MOUSE 5.75 68.648 Decreased 1.3
1109 Serum albumin precursor [Mus musculus] ALBU_MOUSE 5.75 68.648 Decreased 1.6
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range of pH 4–7, respectively. Transcriptomics and pro-
teomics provided complementary data and led us to ana-
lyse both gene expression by qPCR and protein
abundance by western blotting for some candidate targets.
As expected, the expression of several genes and abun-
dance of proteins involved in muscle energy metabolism
were altered. Specifically we found an up-regulation of
those involved in glycolytic metabolism and a down-reg-
ulation of mitochondrial proteins. Similar to previously
published results [27-29], this provided additional evi-
dence of a glycolytic shift within skeletal muscle in
absence of functional myostatin. Additionally, expression
level of α1-syntrophin, a predominant syntrophin iso-
form in skeletal and cardiac muscle, significantly
increased in MSTN-null mice. This result is in agreement
with the work of Vandebrouck and co-workers [30],
which indicates that α1-syntrophin might play a potential
signalling role in the regulation of calcium influx in mus-
cle cells and thereby regulate muscle activity.
Increased potential for PI3K pathway
Our study revealed that upstream components of the
PI3K/Akt/GSK-3β, a signalling network that promotes cell
survival and proliferation, were targets of myostatin inac-
tivation. The core of the PI3K signalling pathway begins
with PI3K activation and subsequent generation of the
second messenger lipid phosphatidyl (3,4,5) triphos-
phate, which recruits and activates PI-dependent kinase.
The latter phosphorylates and activates protein kinase B/
Akt [31]. GSK-3β is a substrate for phosphorylated Akt
and is inactivated upon phosphorylation. We detected the
differential expression of mRNAs that encode for PIK3R3,
PIK3CG, PLCG1, and GSK-3β. Increases in the abundance
of phophorylated-Akt and in the activation ratio of GSK-
3β (phosphorylated GSK-3β at serine 9/GSK-3β) were also
detected (Table 2). This finding is original since the PI3K
pathway is mainly regulated through post-translational
modification namely phosphorylation. Thus, our results
indicate that myostatin inactivation resulted in increased
potential for PI3K/Akt activation and decreased potential
for GSK-3β activity both at the transcriptional and post-
translational levels.
Interestingly, we also detected the differential abundance
of factors regulating the PI3K pathway e.g. DJ-1, PTEN and
PINK1. DJ-1, a cancer- and Parkinson's disease-associated
protein also called park7, protects cells from toxic stresses
and is implicated in mitochondria and oxidative stress-
related survival pathways (reviewed in [32]). It associates
with chaperonnes including mortalin. DJ-1 has also been
reported to be a novel regulator of the PI3K-PTEN path-
way [33]. The tumour-suppressor phosphatase with
tensin homology (PTEN) is the most important negative
regulator of the cell-survival signalling initiated by PI3K
(Figure 1). DJ-1 interacts with PTEN-induced putative
kinase 1 (PINK1), which encodes a Ser/Thr kinase with a
mitochondrial-targeting signal, and collaborate to protect
cells against oxidative stress induced cell death [34]. Inter-
estingly, our data show up-regulation of DJ-1 and PINK1
and down-regulation of PTEN both at the transcriptional
and protein levels and this could account for activation of
the PI3K pathway in MSTN-null mice.
Abundance of candidate proteins to be myostatin targets as revealed by western-blotting in the muscles of control and MSTN- ull miceFigur  1
Abundance of candidate proteins to be myostatin 
targets as revealed by western-blotting in the mus-
cles of control and MSTN-null mice. A-D: control mice; 
E-H: MSTN-null mice. pAkt: phosphorylated akt; GSK-3β: 
Glycogen synthase kinase 3β; GSK-3β (ser9): Glycogen syn-
thase kinase 3β (phosphorylated at serine 9); DJ-1: cancer- 
and Parkinson's disease-associated protein (park7); PINK1: 
PTEN-induced putative kinase 1; PTEN: tumour-suppressor 
phosphatase with tensin homology. TCTP: Translationally 
controlled tumor protein; 14-3-3E: 14-3-3ε protein. Actin 
was used as a loading control protein.
GSK-3ȕ
(total)
A B C D E F G H
Actin
DJ-1
PTEN
p-Akt
PINK1
TCTP
A B C D E F G H
Actin
14-3-3E
GSK-3ȕ (ser9)
1739 ATP synthase D chain, mitochondrial [Mus 
musculus]
ATP5H_MOUSE 5.52 18.607 Decreased 1.3
1152 Succinate dehydrogenase [ubiquinone] 
flavoprotein subunit, mitochondrial 
precursor [Mus musculus]
DHSA_MOUSE 7.06 72.539 Decreased 1.7
1400 Ubiquinol-cytochrome-c reductase complex 
core protein I, mitochondrial precursor 
[Mus musculus]
UQCR1_MOUSE 5.75 52.735 Decreased 1.5
1608 Troponin T, fast skeletal muscle (TnTf) (Fast 
skeletal muscle troponin T) (fTnT) [Mus 
musculus]
TNNT3_MOUSE 5.26 32.09 Decreased 1.6
Accession number: reference of each protein in Swiss-Prot database; pI: isoelectric point; Mr (kDa): molecular weight; FC: Fold-Change
Table 3: Differentially expressed muscle proteins in myostatin-null mice vs control mice. (Continued)
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The PI3K/Akt pathway plays a pivotal role in the promo-
tion of cell proliferation and inhibition of cell death. It
plays an important role in at least two signal transductory
systems, namely, the Wnt/wingless and PI3K pathways,
which influence proliferation and cell survival, respec-
tively. Our data agree well with data that demonstrate a
correlation between activation of PI3K pathway and
increase in cell size [35] and the activation of Akt, which
stimulates muscle hypertrophy and antagonizes the loss
of muscle protein [36]. Akt signalling through GSK-3β,
mTOR (a PI3K-related kinase) and Foxo1 was shown to be
associated with skeletal muscle hypertrophy and atrophy
processes in humans [37]. Recently, Amirouche and work-
ers have shown that MSTN negatively regulates Akt/mTOR
signalling pathway [38]. It was also shown that MSTN
activates GSK-3β and decreases cyclin D1 by inhibiting
the PI3K/Akt pathway and this has been proposed to be
involved in the progression of muscle-disuse atrophy
[39]. Lastly, the PI3K/Akt pathway is the major intracellu-
lar pathway activated by IGF-I stimulation during myo-
genesis [40]. A primary effect of GSK-3β inhibition in
muscle is to promote myogenic differentiation and it has
been proposed that IGF-mediated hypertrophy involves
the negative regulation of GSK-3β activity [41].
Altered expression/abundance of factors involved in cell 
survival/apoptosis
Our data revealed changes in the expression of genes and
proteins related to cell survival/apoptosis pathways. Actu-
ally, we detected the down-regulation of some factors (e.g.
alpha crystallin-related B6, heat shock protein 9A) and
up-regulation of others (e.g. Dad1, survivin, TCTP, 14-3-
3E) that may be a signature of increased cell survival and
anti-apoptotic processes. Indeed, alpha crystallin-related
B6, a heat shock protein 20, is thought to protect cells
from apoptosis [42]. Heat shock protein 9A (Mortalin,
Grp75), a member of the heat shock protein 70 family,
plays a central role in mitochondrial import, energy gen-
eration and chaperoning of mis-folded proteins (for
review [43]). This factor interacts with the tumor suppres-
sor protein p53 and inactivates its transcriptional activa-
tion and apoptotic functions [44]. Up-regulation of
mortalin contributes significantly to tumorigenesis [45].
Dad1 (defender against apoptotic death) has been
reported to be a programmed cell death suppressor neces-
sary for cell survival in a mammalian cell line [46] and the
loss of Dad1 protein triggers apoptosis [47]. Survivin
(Birc5) is a member of the inhibitor of apoptosis (IAP)
family that prevents apoptotic cell death in various cell
types including hematopoietic, endothelial, embryonic
and neuronal cells [48]. Translationally controlled tumor
protein (TCTP) is involved in the calcium binding and
microtubule stabilization [49] and has been implicated in
cell growth, cell cycle progression, malignant transforma-
tion and in protection of cells against various stress condi-
tions and apoptosis [50]. 14-3-3E is a member of the 14-
3-3 family of phosphoserine-binding adapter molecules
that mediate a general survival-promoting function
through interaction with target proteins, by enhancing
pro-survival signalling while suppressing activity of pro-
apoptotic proteins (reviewed by [51]). They are involved
in the regulation of apoptosis through multiple interac-
tions with proteins of the core mitochondrial machinery,
pro-apoptotic transcription factors and their upstream sig-
nalling pathways. One prominent mechanism for the sup-
pression of apoptosis is through 14-3-3-mediated
sequestration of pro-apoptotic proteins (e.g. BAD, Bcl-2-
antagonist of cell death; [52]). Furthermore, 14-3-3 pro-
teins regulate the Akt/mTOR pathway via interaction with
PRAS40, a mTOR binding partner [53]. In our study, 14-
3-3E showed greater expression in the hypertrophied
muscles of MSTN-null mice. Interestingly, some of the dif-
ferential proteins detected in our study (e.g. DJ-1, T-com-
plex protein 1, proteasome B chain) were reported to
belong to the 14-3-3 interacting "phosphoproteome"
[54].
Interestingly, in a previous study conducted in the context
of MSTN loss of function in cattle [28], we have already
found an up-regulation of genes encoding proteins
involved in apoptosis (e.g DDX, PDCD6) and a down-reg-
ulation of anti-apoptotic genes belonging to the Bcl2 fam-
ily. Supporting the hypothesis of decreased apoptosis in
the muscles of MSTN-null mice, we found that the bioac-
tive fragment of the initiator Caspase 8 was decreased in
these mice compared to their littermates (data not
shown). The functional significance of proteins related to
cell survival/apoptosis to muscle hypertrophy remains to
be further studied. However, the results of the present
study suggest that MSTN may behave as an arbiter of the
survival decision in the muscles. In MSTN-null mice,
increased abundance of anti-apoptotic factors probably
induces a by-pass of apoptosis and consequently
increased cell survival, a process leading to hypertrophy
(Figure 1). The involvement of MSTN in apoptosis
remains scarce and controversial. There are conflicting
results regarding MSTN and apoptosis. It is not clear
whether this factor protects myoblasts from apoptosis
[14,55] or promotes the apoptotic process [39,56]. This
discrepancy may be explained by the different experimen-
tal conditions in which MSTN effect was examined in vitro
(e.g. proliferation vs differentiation phase, myogenic cell
lines vs primary myoblast cultures). Although skeletal
muscle is considered to be rather resistant to apoptosis
partly due to high concentration of endogenous inhibi-
tors (reviewed in [57]), there is evidence that apoptotic
events occur in skeletal muscle under physiological (exer-
cise) and pathological conditions (e.g. muscle disuse-
induced atrophy, denervation, ageing, dystrophinopa-
thies) and may contribute to atrophy and loss of fibers
BMC Genomics 2009, 10:196 http://www.biomedcentral.com/1471-2164/10/196
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[58-61]. "Myonuclear apoptosis" is a predominant form
of apoptosis by which a loss of myonuclei occurs without
cell death during muscle atrophy [62,63]. This process
may have major consequence since (1) the number of
myonuclei is a critical determinant for protein synthesis
capacity (2) apoptosis within muscle may alter the myo-
nuclear to cytosolic ratio (protein/DNA). Thus, modula-
tion of myonuclear number or myonuclear domain size
or both is a mechanism by which MSTN may contribute
to muscle homeostasis. Inhibition of apoptosis in the
context of MSTN loss-of-function could lead to increased
myonucler survival and consequently to increased protein
biosynthesis. Thus, this could contribute to the hyper-
trophic pathway, especially in growing mice. Work is
progress to assay apoptotic process in muscles according
to MSTN activity.
Conclusion
In conclusion, integration of transcriptomic and pro-
teomic data indicate that MSTN inactivation could pro-
mote survival and resistance to apoptosis in muscle
through the PI3K/Akt/GSK-3β survival pathway and
through a mechanism that involves regulation of pro- and
anti-apoptotic factors. A combination of increased poten-
tial for PI3K activation and decreased myonuclear apopto-
sis could be crucial to muscle hypertrophy in MSTN-null
mice (Figure 2).
Methods
Muscle samples
The MSTN-null mice have a constitutive invalidation of
myostatin gene [7]. These mice were bred at the Iowa State
University, were slaughtered at 5 weeks postnatally, were
dissected and their muscle masses were weighted. At this
age the mice were nearly adults and this developmental
stage was chosen in order to dissociate the influence of
MSTN on hypertrophy from that of myofiber hyperplasia.
Muscle samples were taken from Quadriceps muscle
(mixed slow oxidative) immediately after slaughter, fro-
zen in liquid nitrogen and kept at -80°C until protein
extraction was performed. The Quadriceps muscle was cho-
sen for the genomic experiments owing to its weight and
marked hypertrophy (+87%, data not shown).
Microarray experiments
Transcriptomic analysis was performed with a microarray
of 6,473 genes expressed in muscle ("Myochips" available
from OUEST-genopole®, France) as described in [28].
These Myochips consisted in 6,473 oligonucleotides from
human (76%) and murine (24%) origin and 919 con-
trols. Microarray experiments were performed according
to recently proposed standards (MIAME consortium).
Data were incorporated into the BASE database and the
NCBI Gene Expression Omnibus (GEO) http://
www.ncbi.nlm.nih.gov/projects/geo/ and are accessible
through GEO Series GSE5561 and GSE5456.
Total RNA was extracted from muscle tissue samples with
TRIZOL® reagent (Life Technologies) according to the
manufacturer's recommendation. The RNA was then puri-
fied and treated with DNAse using the RNeasy® Mini kit
(Qiagen, France). RNA integrity was checked using Lab
Chip Agilent technology, as previously described [28].
Each individual sample was compared to a reference pool
consisting of skeletal muscle transcripts isolated from dif-
ferent muscles of four mice lines (Balb, C57bl6, B129) of
different age and gender, and from cultured murine myo-
genic cells (C2C12).
Labeling was performed using a "Pronto Plus Direct Sys-
tems" kit (Corning-Promega) according to the supplier's
guidelines. Five μg of total RNA was reverse transcribed
into cDNA in the presence of cyanine (Cy3-dCTP/Cy5-
dCTP, Amersham). cDNA purification was performed
according to the manufacturer's instructions, and concen-
tration and frequency of incorporation were determined
by spectrophotometry. Three chips were hybridized per
sample comparison. After washing, the chips were
scanned on an Affymetrix 428™ Array Scanner. Images
were analyzed using GenePix Pro V6 software (Axon
instrument, Inc). Raw intensity data were normalized
using the MADSCAN program (http://cardios
erve.nantes.inserm.fr/mad/madscan/, 15). In order to
identify differentially expressed genes, the Cy3/Cy5 ratios
were statistically analyzed using Significance Analysis of
Microarrays (SAM) method (FDR <5%; [64]). With the
available sample size (4 animals per group) and 3
repeated measurements per sample and taking account a
test power (1-β) set at 80% [65,66] and the biological var-
iability (Standard Deviation SD = 0.083), the minimum
difference was 11% corresponding to a threshold fold-
change (FC) of 1.11. Thus we only retained appropriately
powered genes.
Proteomics
Preparation of muscle samples for 2-DE
Sample preparation was performed according to Bouley et
al. [67]. Briefly, frozen muscle tissue (50–100 mg) was
homogenized in a lysis buffer containing 8.3 M urea, 2 M
thiourea, 1% DTT, 2% CHAPS and 2% IPG buffer pH 3–
10 with a polytron and centrifuged at 10,000 g for 30 min.
The supernatant was harvested and protein concentration
for each sample was determined as described in the Plu-
sOne 2-DE Quant kit (Amersham Biosciences).
Protein quantification was determined using the 2-DE
Quant kit (Amersham Uppsala, Sweden), with bovine
serum albumin as a standard. Average amount of protein
was 9.6 μg. μl-1 ± 1.48 μg.μl-1.
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2-DE separation
2-DE separation was performed according to the method
of Bouley et al. [67]. Briefly, for the first dimension (IEF),
proteins were solubilized in a rehydration solution (8 M
urea, 1 M thiourea, 0.28% DTT, 2% CHAPS, 2% IPG
buffer pH 4–7 and 0.01% CBBR-250). IPG strips, 18 cm,
covering a pH range of 4–7 were rehydrated overnight in
330 ml of this protein solution under low viscosity paraf-
fin oil (sample loading by rehydration). IPG strips con-
taining 700 μg of proteins were subjected to IEF (73.5
kVh) in a Multiphor II gel apparatus at 20.5°C. After com-
pletion of the IEF, proteins on the strip were equilibrated
for 15 min in a buffer containing 6 M urea, 1% DTT, 30%
glycerol, 50 mM Tris base, 2% sodium dodecyl sulphate
(SDS), and DTT and then for an additional 15 min in the
same solution except that DTT was replaced by 5% iodoa-
cetamide and 0.002% bromophenol blue was added. The
IPG strips were then transferred onto 11% T, 2.6% C sep-
arating polyacrylamide gels, and proteins were separated
in the second dimension using a Hoefer DALTsix system
(Hoefer, Scientific Instruments, San Francisco, CA, USA).
2-DE gels were stained using a colloidal CBB G-250 pro-
cedure [67] and digitized on a calibrated scanner (ImageS-
canner, Amersham).
Image and Data analysis
ImageMaster 2D Platinum software (Amersham Bio-
sciences) was used to match and quantify protein spots on
2-DE gels. Parameters used for spot detection were mini-
mal area = 70 pixels, smooth factor = 2.0, and saliency =
20. An artificial reference gel was created combining all
the spots present in the different gels. The reference gel
was then used for matching of corresponding protein
spots between gels. The volume of individual spot was
normalized (% volume) according to the mean volume of
249 protein spots which were strictly common to all gels.
Comparisons between groups were performed using SAM
statistical test [68]. Differences were declared significant
for FDR <5%. Taking into account the biological variabil-
ity which is 21%, the power analysis [66] allowed retain-
ing proteins which present a minimum difference of 41%
corresponding to a threshold FC of 1.41.
Identification of spots by Mass Spectrometry
All differential protein spots were excised from the poly-
acrylamide gel and placed in a Multiscreen solvinert 96-
well filtration system plate (Millipore Corp., Bedford,
MA). These proteins of interest were digested proteolyti-
cally in the plate with 3 volumes of trypsin solution (10
ng/μL; V5111, Promega, Madison, WI) at 37°C for 5 h
and extracted with 8–12 μL of ACN. The resulting peptide
fragments were mixed with an equal volume of CHCA sat-
urated solution in 0.1% TFA, 50% aqueous ACN.
Peptide mass fingerprintings (PMF) of tryptic peptides
were identified in a positive reflectron mode using a voy-
ager DE Pro MALDI-TOF (Perspective Biosystem, Farm-
inghan, MA, USA). External calibration was performed
with a standard peptide solution (Proteomix, LaserBio
Labs, Sophia-Antipolis, France). Internal calibration was
performed using peptides resulting from auto-digestion of
porcine trypsin, with protonated masses of 842.509,
1045.564, and 2211.104 Da. Peptides mass fingerprints
were compared with mammalian databases [NCBI http://
www.ncbi.nlm.nih.gov/Database/ and SWISS-PROT
http://www.expasy.org/sprot/] using MASCOT and Pro-
Found software [http://www.matrixscience.com and
http://prowl.rockefeller.edu, respectively (June 2007 and
October 2007)].
The search criteria used were 1 missing trypsin cleavage
site, partial methionine oxidation, partial carbamid-
In MSTN-null mice, regulators of the PI3K pathway and cell survival/apoptosis lik ly contribute to muscle ypertrophyFigure 2
In MSTN-null mice, regulators of the PI3K pathway 
and cell survival/apoptosis likely contribute to muscle 
hypertrophy. PI3K signalling pathway: PI3K, Phosphatidyl 
Inositol 3 Kinase; Akt, protein kinase B; GSK-3β, Glycogen 
synthase kinase 3β; eIF2B, eukaryotic protein synthesis initia-
tion factor 2B; PTEN, tumour-suppressor phosphatase with 
tensin homology (the most important negative regulator of 
the cell survival signalling initiated by PI3K); DJ-1, a cancer- 
and Parkinson's disease-associated protein (a novel regulator 
of the PI3K-PTEN pathway). Survival/Anti-apoptotic factors: 
PINK1, PTEN-induced putative kinase; Dad1, defender 
against apoptotic death; TCTP, Translationally controlled 
tumour protein; 14-3-3E, 14-3-3 protein epsilon; Birc5, sur-
vivin.
N DJ-1
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omethylation of cysteine and mass deviation lower than
30 ppm. We required at least 5 matched peptides per pro-
tein for identification and used the ProFound and MAS-
COT probabilistic score and the accuracy of the
experimental-to-theoretical isoelectric point (pI) and
molecular weight (Mr).
Bioinformatic tools
To understand biological function or molecular mecha-
nism of the main molecular targets of MSTN, we used a set
of bioinformatics web tools such as Genomatix, DAVID
and PANTHER for gene identification and String for inter-
actions networks between proteins. The data mining
allowed to visualize KEGG (Kyoto Encyclopedia of Genes
and Genomes) pathway and to classify gene and protein
by their function.
Validation of Proteins and genes expression
Western blotting
Western-blotting was used to validate the main differen-
tially expressed proteins. These proteins were separated by
gel electrophoresis using SDS-PAGE for 2 h. After migra-
tion, the proteins were transferred onto PVDF transfer
membrane Millipore (Dutscher Dominique SAS, France).
Membranes were then blocked with 5% non-fat milk in T-
TBS 1× buffer containing (blocking solution) and incu-
bated under gentle agitation all the night at room temper-
ature in the presence of the a primary antibodies: DJ-1,
1:2000 dilution of purified rabbit polyclonal anti-DJ-1
antibody (sc 32874, Santa Cruz); MyBP, 1:4000 dilution
of purified mouse monoclonal anti-MyBP antibody
(H0000 4608-MO1, ABNOVA); TCTP, 1:2000 dilution of
purified rabbit polyclonal anti-HRF antibody (sc 30124,
Santa Cruz); 14-3-3ε, 1:4000 dilution of purified goat pol-
yclonal anti-14-3-3ε protein antibody (sc 1615, Santa
Cruz); α-1 syntrophin, 1:500 dilution of purified rabbit
polyclonal anti-SNTA1 antibody (sc- 50460, Santa Cruz);
H-FABP, 1:2000 dilution of purified rabbit polyclonal
anti-H-FABP, was a gift from Dr. Jacques Veerkamp and
Dr. Herman Van Moerkerk (Dept. Biochemistry,
Nijmegen, Netherlands) [63]; mortalin, 1:250 dilution of
purified mouse monoclonal anti-GRP75 antibody
(MAB3584, Clone 419612, R&D systems); PINK1, 1:2000
dilution of purified rabbit polyclonal anti-PINK1 anti-
body (sc- 33796, Santa Cruz); GSK-3β, 1:2000 dilution of
purified rabbit polyclonal anti-GSK-3β antibody (sc-
9166, Santa Cruz); GSK-3β (ser9), 1:4000 dilution of
purified goat polyclonal anti-p-GSK-3β (Ser9) antibody
(sc- 11757, Santa Cruz); MyHC, 1:2000 dilution of puri-
fied mouse monoclonal anti-MyHC antibody [S5 8H2,
lot: 9013-1, obtained under "Noé" project who associates
our team and Biocytex company [69] and now this anti-
body is commercialized by Agro-Bio society]; PTEN,
1:2000 dilution of purified rabbit polyclonal anti-PTEN
antibody (sc- 9145, Santa Cruz); p-Akt, 1:2000 dilution of
purified rabbit polyclonal anti-p-Akt 1/2/3 (Ser473) anti-
body (sc- 33437-R, Santa Cruz); Actin, 1:20000 dilution
of purified mouse monoclonal anti-actin antibody
(IgG2a, Clone AC40, Sigma Chemical Company, St Louis,
MO, USA), which are able to bind to its specific protein.
The blots were extensively washed with Tris buffer and
incubated under gentle agitation with the secondary anti-
bodies (anti-mouse, anti-goat or anti-rabbit IgG com-
bined with conjugated with horseradish peroxidase 1:
20000 dilution) for 1 h. The activity of the enzyme was
revealed by Enhanced Chemiluminescence kit (Amer-
sham).
The power analysis [66] allowed retaining proteins which
present a minimum difference of 45% corresponding to a
threshold FC of 1.45.
Real-Time Polymerase Chain Reaction Analysis
Seven genes shown to be differentially expressed were
selected from the results obtained by microarray analysis
and by proteomic analysis. The quantitative RT-PCR
(qPCR) was realized using SYBR Green I dye. PCRs were
performed using gene-specific primers pairs (Table 4). The
Table 4: Primer sequences used in quantitative real-time PCR.
Gene Symbol Forward primer Reverse primer
DJ-1 AACACACCCACTGGCTAAGG GGGCTTGGGCTCTAGTCTTT
Ywhae GAGGTGTTTTGGGGGAGTTT GGCTTCCATACCACCTTCAA
HSPA9 GCCGTTTCCAGTGCAACAAG GATGCTGCCGTCCTGATGTT
GSK-3β CTCTGGCCACCATCCTTATC GTTCAGGTGGAGTTGGAAGC
PTEN TGCAGAAAGACTTGAAGGTG ATAAGTTCTAGCTGTGGTGG
Pi3Kr3 ATGAGAACCTGCCGCATTAT GAATGCACCATCTGGTTTCC
mfgf6 ATTGGGAAAGCGGCTATTTGC CTCGTGTGTTCCACTGATGC
mS6R TTTGATTCTGAAAGCCATGCG CGGTCCATCAGGATTCTATTG
All primer sequences were designed with the Primer3 software.
DJ-1: cancer- and Parkinson's disease-associated protein (park7); 14-3-3E: 14-3-3ε protein; HSPA9: mortalin, GSK-3β: Glycogen synthase kinase 3β; 
PI3KR3: Phosphatidylinositol 3-kinase regulatory subunit; PTEN: tumour-suppressor phosphatase with tensin homology; mfgf6: murine Fibroblast 
growth factor 6; mS6R: mouse ribosomal protein S6.
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absolute quantity of each target gene was determined by
using serially diluted standards to generate a standard
curve. The concentration in pg/μmol of each gene was
determined by using a linear relationship between
amounts of standards cDNA and their Ct (Cycle thresh-
old). Real-Time PCR experiment was controlled using the
ribosomal protein S6 as reference gene. The power analy-
sis [66] allowed retaining genes which present a mini-
mum difference of 54% corresponding to a threshold FC
of 1.54.
Western-blot and RT-PCR data analysis
The difference of proteins and genes levels between
myostatin-null mice and their controls was analyzed by
Student t-test. Results are expressed as the mean ± stand-
ard error of mean (SEM). A difference between the two
groups was considered significant when P < 0.05.
Abbreviations
MSTN: myostatin; SAM: Significance Analysis of Microar-
rays; DNA: Desoxyribo Nucleic Acid; FC: Fold Change;
FDR: False Discovery Rate; PI3K: the Phosphatidyl Inosi-
tol 3-kinase.
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